Anoop M. Nambiar

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Jamie N. Justice, Anoop M. Nambiar, Tamar Tchkonia et al. · EBioMedicine · 2019 · 1.1K citations · Full text

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection

Tanayott Thaweethai, Sarah E. Jolley, Elizabeth W. Karlson et al. · JAMA · 2023 · 792 citations · Full text

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

Anoop M. Nambiar, Dean L. Kellogg, Jaime Justice et al. · EBioMedicine · 2023 · 207 citations · Full text

Pulmonary function measures predict mortality differently in IPF <i>versus</i> combined pulmonary fibrosis and emphysema

S. Schmidt, Anoop M. Nambiar, Nabihah Tayob et al. · European Respiratory Journal · 2010 · 164 citations · Full text